REM-001
Phase 2- Indications
- Cutaneous metastatic breast cancer, Recurrent basal cell carcinoma, Nevus syndrome
Company intelligence / Profile preview
Kintara Therapeutics
San Diego, California, United Stateskintara.com ↗
- Ownership
- Public · KTRA
- Employees
- ~1
- Development stage
- Phase 2
01
Overview
REM‑001 has demonstrated an approximately 80% complete response rate in evaluable cutaneous metastatic breast cancer lesions across multiple late-stage trials. The safety database includes nearly 1,100 patients across various indications. Current open-label studies are ongoing to optimize dosing and support future Phase III development. NIH SBIR funding supports the current trial. FDA fast track designation granted for REM‑001 in CMBC.
- Therapeutic areas
- OncologyNephrology
- Modalities
- Photodynamic therapy (PDT)Small molecule DNA-targeting agent (VAL-083)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborations with leading academic and clinical research institutions globallypartnership/merger agreement with TuHURA Biosciences announced April 2024
Beyond the preview
Go deeper on Kintara Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kintara Therapeutics.